Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Cash from Investing Activities: 2011-2025

Historic Cash from Investing Activities for Adma Biologics (ADMA) over the last 10 years, with Sep 2025 value amounting to -$14.4 million.

  • Adma Biologics' Cash from Investing Activities fell 1208.56% to -$14.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$24.4 million, marking a year-over-year decrease of 236.91%. This contributed to the annual value of -$8.6 million for FY2024, which is 72.15% down from last year.
  • Per Adma Biologics' latest filing, its Cash from Investing Activities stood at -$14.4 million for Q3 2025, which was down 468.58% from -$2.5 million recorded in Q2 2025.
  • Over the past 5 years, Adma Biologics' Cash from Investing Activities peaked at -$757,000 during Q3 2023, and registered a low of -$14.4 million during Q3 2025.
  • Over the past 3 years, Adma Biologics' median Cash from Investing Activities value was -$2.4 million (recorded in 2024), while the average stood at -$3.2 million.
  • In the last 5 years, Adma Biologics' Cash from Investing Activities spiked by 77.87% in 2023 and then plummeted by 1,208.56% in 2025.
  • Adma Biologics' Cash from Investing Activities (Quarterly) stood at -$3.7 million in 2021, then dropped by 1.98% to -$3.7 million in 2022, then soared by 62.46% to -$1.4 million in 2023, then crashed by 95.45% to -$2.8 million in 2024, then crashed by 1,208.56% to -$14.4 million in 2025.
  • Its Cash from Investing Activities was -$14.4 million in Q3 2025, compared to -$2.5 million in Q2 2025 and -$4.7 million in Q1 2025.